Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05438563 · ClinicalTrials.gov registry record · NA

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

A NA study of Prostate Carcinoma and Stage II Prostate Cancer AJCC v8, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT05438563: Recruiting NA study of Prostate Carcinoma and Stage II Prostate Cancer AJCC v8, sponsored by Mayo Clinic.

NCT05438563 is a NA study of Prostate Carcinoma and Stage II Prostate Cancer AJCC v8 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05438563, a NA study of Prostate Carcinoma and Stage II Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer. MRI-guided TULSA ablation is a minimally invasive procedure that uses an ultrasound device guided by MRI imaging to deliver high-energy sound waves, producing very high temperature to ablate (destroy) tumor cells in a targeted manner. The MRI-guided TULSA procedure may help patients avoid surgery and help improve prostate cancer patients' quality of life.

Primary Outcome

Failure is defined as: delivery of any additional intervention for prostate cancer (local or systemic, including adjuvant therapy); or metastatic disease; or prostate cancer-specific death.

Interventions

  • PROCEDURE Biopsy
  • OTHER Questionnaire Administration
  • PROCEDURE Cystoscopy
  • PROCEDURE MRI-Guided Transurethral Ultrasound Ablation
  • PROCEDURE Digital Rectal Examination

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-04-06
Est. Completion 2027-03-07
Phase NA
Mayo Clinic

2,844 total trials

What NCT05438563 shows while recruiting

NCT05438563 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (93% lower).

The record links to 3 conditions, with Prostate Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biopsy is the first listed.

NCT05438563 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05438563 about?

NCT05438563 is a clinical study titled "MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer". This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer. MRI-guided TULSA ablation is a minimally invasive procedure that uses an ultras...

What is the current status of trial NCT05438563?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-04-06. Estimated completion is 2027-03-07.

What conditions does trial NCT05438563 study?

This clinical trial studies the following conditions: Prostate Carcinoma, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8.

What interventions are being tested in trial NCT05438563?

The interventions under investigation include: Biopsy (PROCEDURE), Questionnaire Administration (OTHER), Cystoscopy (PROCEDURE), MRI-Guided Transurethral Ultrasound Ablation (PROCEDURE), Digital Rectal Examination (PROCEDURE).

Who is sponsoring clinical trial NCT05438563?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05438563 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05438563's enrollment target sits among peer trials

100 26th of 59 higher than 33 of 59 other Prostate Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05438563, the US trial registry maintained by the National Library of Medicine. NCT05438563 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.